| Patrick Almeter, | |
|
934 Dougherty Rd, Aiken, SC 29803-6515 | |
| (803) 643-0588 | |
| Not Available |
| Full Name | Patrick Almeter |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 9 Years |
| Location | 934 Dougherty Rd, Aiken, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578933057 | NPI | - | NPPES |
| 003190113C | Medicaid | GA | |
| 003190113E | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 8336 (Georgia) | Secondary |
| 363A00000X | Physician Assistant | PA2425 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital | Augusta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vascular Radiology Associates, Ii | 1456345651 | 13 |
News Archive
While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
The editors of the journal Science have selected a Mayo Clinic discovery as one of their top 10 "groundbreaking scientific achievements of 2011." The Mayo study -the first to eliminate the effects of aging in mice - received worldwide attention when it was published in Nature in November.
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge, and the AstraZeneca IMED Biotech Unit reveals new insights into how the PTEN gene may control cell growth and behavior and how its loss contributes to the development and advancement of certain cancers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Almeter, 934 Dougherty Rd, Aiken, SC 29803-6515 Ph: (803) 643-0588 | Patrick Almeter, 934 Dougherty Rd, Aiken, SC 29803-6515 Ph: (803) 643-0588 |
News Archive
While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
The editors of the journal Science have selected a Mayo Clinic discovery as one of their top 10 "groundbreaking scientific achievements of 2011." The Mayo study -the first to eliminate the effects of aging in mice - received worldwide attention when it was published in Nature in November.
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge, and the AstraZeneca IMED Biotech Unit reveals new insights into how the PTEN gene may control cell growth and behavior and how its loss contributes to the development and advancement of certain cancers.
› Verified 9 days ago
Tori Jolly, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 131 Rinehart Way, Aiken, SC 29803 Phone: 803-335-2200 Fax: 803-649-7966 | |
Erin P Stewart, P.A.-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 131 Rinehart Way, Aiken, SC 29803 Phone: 803-335-2200 Fax: 803-649-7966 | |
Mr. William Kevin Higgins, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 302 University Pkwy, Aiken, SC 29801 Phone: 806-641-5100 | |
Mr. Michael Edward Spillane, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 440 Society Hill Dr Ste 100a, Aiken, SC 29803 Phone: 032-260-1028 Fax: 803-226-0384 | |
Ms. Veronica Marie Chavis, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 137 Miracle Drive, Nw, Aiken, SC 29801 Phone: 803-641-4874 Fax: 803-641-0436 | |
Jory Gibbons Croft, P.A. Physician Assistant Medicare: Medicare Enrolled Practice Location: Aiken Specialty Services, 209 Abbeville Ave Nw, Aiken, SC 29801 Phone: 803-306-1433 | |
Stephen Rozier, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1520 Two Notch Rd Se, Aiken, SC 29803 Phone: 803-649-3909 Fax: 803-642-8495 |